Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

7 days ago

BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies ...

Ticker	Sentiment	Impact
BOLT	Neutral	24 %